Bound Brook, NJ (October 22, 2015) DZS Software Solutions, Inc. today announced the release of ClinPlus CTMS version 2.3, a Clinical Trial Management System (CTMS) that includes 70 enhancements, most of which were inspired by customer feedback.
“Because DZS Software Solutions, Inc. is a customer focused company, their requests were given serious consideration and are the driving force behind Version 2.3,” said Bob Borysko, Vice President of Business Development. “As new clients come online they invariably will have unique requirements they would like to see addressed in the software. Our software engineers evaluate each request and design solutions that will not only satisfy the client making the request, but also may benefit the entire user base and improve overall marketability. This customer focused design philosophy is the primary reason for our high level of customer satisfaction and accelerating rate of new client adoption.”
Version 2.3 adds the ability to support read-only licenses and every ClinPlus CTMS client will receive five at no additional cost. Other areas of improvements include:
The development process continues toward the next major release for 2016, ClinPlus eClinical 3, which will not only include significant enhancement to CTMS but will also incorporate full EDC capabilities within the eClinical platform. To learn more, contact Bob Borysko at (732) 764-6969.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.